Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00661_DB01263_nanopub.RAEvt-JO5YRSrOEkpUP2ZhhPBLCaBXVu-47Y8M1Svw208#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00661_DB01263 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB01263 label "DDI between Verapamil and Posaconazole - Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB01263]" assertion.
- drugbank_resource:DB00661_DB01263 identifier "drugbank_resource:DB00661_DB01263" assertion.
- drugbank_resource:DB00661_DB01263 title "DDI between Verapamil and Posaconazole - Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01263 assertion.
- drugbank:DB01263 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01263 assertion.